Q2 2017 and investor event
We announced our second quarter 2017 results on 26 July and hosted an investor event where Emma Walmsley, CEO, and Simon Dingemans, CFO, spoke about our strategic priorities and financial outlook.
- Q2 2017 results announcement PDF - 1.9MB
- Q2 2017 results video transcript PDF - 177.6KB
- Q2 2017 US dollar translation PDF - 121.7KB
- Q2 2017 results infographic PDF - 862.6KB
- Q2 2017 pre announcement aide memoire PDF - 795.1KB
- Emma Walmsley slides: Key priorities PDF - 864.3KB
- Simon Dingemans slides: Q2 and financial outlook PDF - 509.3KB
- Investor event full transcript PDF - 173.6KB
2012 Fourth Quarter - released 06 February 2013
Simon Dingemans, CFO, and Sir Andrew Witty, CEO, discuss our fourth quarter results 2012.
- Core EPS of 112.7p and returns of £6.3bn to shareholders
- 2012 dividend of 74p (+6%)
- Group sales -1%; flat excluding disposals of OTC brands
- Successful R&D delivery: six new drugs filed since start of 2012
2012 Third Quarter - released 31 October 2012
Simon Dingemans, CFO, discusses our Q3 results 2012.
- Core EPS of 26.5p
- Dividend of 18p (+ 6%)
- Further successful R&D delivery: phase III programmes completed for 6 novel medicines in 2012
- Continued strong cash generation and returns to shareholders
2012 Second Quarter - released 25 July 2012
Watch Sir Andrew Witty, CEO, discuss our second quarter results 2012.
- Core EPS of 26.4p
- Dividend of 17p (up 6%)
- Significant late-stage pipeline delivery
2012 First Quarter - released 25 April 2012
Watch Simon Dingemans, CFO, discuss our first quarter results 2012.
- Sales growth of +2% CER
- Further R&D delivery, operational leverage and continued returns to shareholders
- Core EPS 27.3p (+7%), dividend up 6% to 17p
Other key information
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
Keep up to date with our news and recent announcements
Corporate Executive Team
The Corporate Executive Team manages our activities, and each member is responsible for a specific part of the business
A snapshot of our medicines and vaccines currently in development across three stages: phase I, phase II and phase III